[Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results  from a non-interventional trial].

In conclusion, these results from the daily treatment routine of metastatic pancreatic cancer underline the importance of combined gemcitabine/erlotinib therapy for a subgroup of patients who develop a rash in the course of erlotinib treatment.
PMID: 32052394 [PubMed - as supplied by publisher]

Source: Zeitschrift fur Gastroenterologie - February 11, 2020 Category: Gastroenterology Authors: Westphalen CB, Heinemann V, Tessen HW, Groschek M, Hoeffkes HG, Marschner N, Schulze M, Beringer A, Waldschmidt D Tags: Z Gastroenterol Source Type: research